Therapeutic potential of Lactobacillus casei and Chlorella vulgaris in high-fat diet-induced non-alcoholic fatty liver disease (NAFLD)-associated kidney damages: a stereological study
- PMID: 38704764
- DOI: 10.1007/s11033-024-09542-1
Therapeutic potential of Lactobacillus casei and Chlorella vulgaris in high-fat diet-induced non-alcoholic fatty liver disease (NAFLD)-associated kidney damages: a stereological study
Abstract
Background: The non-alcoholic fatty liver disease (NAFLD) is prevalent in as many as 25% of adults who are afflicted with metabolic syndrome. Oxidative stress plays a significant role in the pathophysiology of hepatic and renal injury associated with NAFLD. Therefore, probiotics such as Lactobacillus casei (LBC) and the microalga Chlorella vulgaris (CV) may be beneficial in alleviating kidney injury related to NAFLD.
Materials and methods: This animal study utilized 30 C57BL/6 mice, which were evenly distributed into five groups: the control group, the NAFLD group, the NAFLD + CV group, the NAFLD + LBC group, and the NAFLD + CV + LBC group. A high-fat diet (HFD) was administered to induce NAFLD for six weeks. The treatments with CV and LBC were continued for an additional 35 days. Biochemical parameters, total antioxidant capacity (TAC), and the expression of kidney damage marker genes (KIM 1 and NGAL) in serum and kidney tissue were determined, respectively. A stereological analysis was conducted to observe the structural changes in kidney tissues.
Results: A liver histopathological examination confirmed the successful induction of NAFLD. Biochemical investigations revealed that the NAFLD group exhibited increased ALT and AST levels, significantly reduced in the therapy groups (p < 0.001). The gene expression levels of KIM-1 and NGAL were elevated in NAFLD but were significantly reduced by CV and LBC therapies (p < 0.001). Stereological examinations revealed reduced kidney size, volume, and tissue composition in the NAFLD group, with significant improvements observed in the treated groups (p < 0.001).
Conclusion: This study highlights the potential therapeutic efficacy of C. vulgaris and L. casei in mitigating kidney damage caused by NAFLD. These findings provide valuable insights for developing novel treatment approaches for managing NAFLD and its associated complications.
Keywords: High fat diet; KIM-1; NGAL; Non-alcoholic fatty liver disease; Oxidative stress.
© 2024. The Author(s), under exclusive licence to Springer Nature B.V.
Similar articles
-
Lactobacillus casei YRL577 combined with plant extracts reduce markers of non-alcoholic fatty liver disease in mice.Br J Nutr. 2021 May 28;125(10):1081-1091. doi: 10.1017/S0007114520003013. Epub 2020 Jul 28. Br J Nutr. 2021. PMID: 32718364
-
Lactobacillus casei YRL577 ameliorates markers of non-alcoholic fatty liver and alters expression of genes within the intestinal bile acid pathway.Br J Nutr. 2021 Mar 14;125(5):521-529. doi: 10.1017/S0007114520003001. Epub 2020 Jul 28. Br J Nutr. 2021. PMID: 32718371
-
Phoenixin 14 Inhibits High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Experimental Mice.Drug Des Devel Ther. 2020 Sep 22;14:3865-3874. doi: 10.2147/DDDT.S258857. eCollection 2020. Drug Des Devel Ther. 2020. PMID: 33061293 Free PMC article.
-
Hepatoprotective Effect of Seed Coat ofEuryale ferox Extract in Non-alcoholic Fatty Liver Disease Induced by High-fat Diet in Mice by Increasing IRs-1 and Inhibiting CYP2E1.J Oleo Sci. 2019 Jun 6;68(6):581-589. doi: 10.5650/jos.ess19018. Epub 2019 May 16. J Oleo Sci. 2019. PMID: 31092797
-
Therapeutic potential of palmitoleic acid in non-alcoholic fatty liver disease: Targeting ferroptosis and lipid metabolism disorders.Int Immunopharmacol. 2024 Dec 5;142(Pt A):113025. doi: 10.1016/j.intimp.2024.113025. Epub 2024 Sep 6. Int Immunopharmacol. 2024. PMID: 39243559
Cited by
-
The prognostic nutritional index as a predictor of cardiovascular and all-cause mortality in chronic kidney disease: a population-based analysis of NHANES data (1999-2018).Front Med (Lausanne). 2025 Jun 6;12:1589173. doi: 10.3389/fmed.2025.1589173. eCollection 2025. Front Med (Lausanne). 2025. PMID: 40547920 Free PMC article.
References
-
- Pouwels S, Sakran N, Graham Y et al (2022) Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. BMC Endocr Disorders 22:1–9
-
- Pai RK (2019) NAFLD histology: a critical review and comparison of scoring systems. Curr Hepatol Rep 18:473–481
-
- Zhang M, Lin S, Wang M-f et al (2020) Association between NAFLD and risk of prevalent chronic kidney disease: why there is a difference between east and west? BMC Gastroenterol 20:1–7
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous